TY - JOUR
T1 - Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer
AU - Lin, Sue Hwa
AU - Lee, Yu Chen
AU - Choueiri, Michel B.
AU - Wen, Sijin
AU - Mathew, Paul
AU - Ye, Xiangcang
AU - Do, Kim Anh
AU - Navone, Nora M.
AU - Kim, Jeri
AU - Tu, Shi Ming
AU - Li-YuanYu-Lee,
AU - Logothetis, Christopher J.
PY - 2008/6/15
Y1 - 2008/6/15
N2 - Purpose: Prostate cancer tends to metastasize to bone and induce osteoblastic lesions. We identified a soluble form of ErbB3 (sErbB3), p45-sErbB3, in bone marrow supernatant from men with prostate cancer bone metastasis and showed that p45-sErbB3 enhances bone formation. We aimed to understand clinical implications of sErbB3 by establishing an ELISA to detect sErbB3 levels in bone marrow and plasma samples. Experimental Design: We did ELISAs on marrow from 108 men [34 with androgen-dependent disease, 30 with androgen-independent disease (Al) but negative bone scan (AI/BS-), and 44 with Al and positive bone scan (AI/BS+)], sequential marrow from 5 men during treatment, plasma from 52 men before and after docetaxel treatment, and plasma from 95 men ages ≥70 years old without prostate cancer. Results: Some men with clinically detectable bone metastasis had high sErbB3 levels. Within the AI/BS- group, higher sErbB3 levels seemed to yield lower rates of bone metastasis. In the AI/BS+ group, detectable bone metastases took longer to appear in men with higher sErbB3 levels than in men with lower sErbB3 levels (median, 82 versus 41 months). However, high sErbB3 levels did not confer survival benefit after metastasis development. Among men with metastatic progression in bone, docetaxel treatment reduced plasma sErbB3 (P < 0.0001) but did not affect bone-specific alkaline phosphatase (P = 0.206) or prostate-specific antigen (P = 0.906). sErbB3 was also detected in men without prostate cancer. Conclusions: The apparent correlation between higher sErbB3 levels and longer time to bone metastasis suggests that sErbB3 participates in progression in bone of prostate cancer.
AB - Purpose: Prostate cancer tends to metastasize to bone and induce osteoblastic lesions. We identified a soluble form of ErbB3 (sErbB3), p45-sErbB3, in bone marrow supernatant from men with prostate cancer bone metastasis and showed that p45-sErbB3 enhances bone formation. We aimed to understand clinical implications of sErbB3 by establishing an ELISA to detect sErbB3 levels in bone marrow and plasma samples. Experimental Design: We did ELISAs on marrow from 108 men [34 with androgen-dependent disease, 30 with androgen-independent disease (Al) but negative bone scan (AI/BS-), and 44 with Al and positive bone scan (AI/BS+)], sequential marrow from 5 men during treatment, plasma from 52 men before and after docetaxel treatment, and plasma from 95 men ages ≥70 years old without prostate cancer. Results: Some men with clinically detectable bone metastasis had high sErbB3 levels. Within the AI/BS- group, higher sErbB3 levels seemed to yield lower rates of bone metastasis. In the AI/BS+ group, detectable bone metastases took longer to appear in men with higher sErbB3 levels than in men with lower sErbB3 levels (median, 82 versus 41 months). However, high sErbB3 levels did not confer survival benefit after metastasis development. Among men with metastatic progression in bone, docetaxel treatment reduced plasma sErbB3 (P < 0.0001) but did not affect bone-specific alkaline phosphatase (P = 0.206) or prostate-specific antigen (P = 0.906). sErbB3 was also detected in men without prostate cancer. Conclusions: The apparent correlation between higher sErbB3 levels and longer time to bone metastasis suggests that sErbB3 participates in progression in bone of prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=52449112465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52449112465&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-08-0472
DO - 10.1158/1078-0432.CCR-08-0472
M3 - Article
C2 - 18559590
AN - SCOPUS:52449112465
SN - 1078-0432
VL - 14
SP - 3729
EP - 3736
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -